2949-7132

Cancer Pathogenesis and Therapy

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 224 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact224 DOIs
2

Attach ORCID iDs across 65 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact65 DOIs
3

Deposit reference lists for 40 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact40 DOIs

DOIs for this ISSN

Showing the top 5 of 224 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Impact of immunosenescence and inflammaging on the effects o… (10.1016/j.cpt.2023.08.001)
Abstract ORCID
73.86 29
2 Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression… (10.1016/j.cpt.2023.11.001)
Abstract ORCID
68.09 22
3 Tumor-associated macrophages (TAMs): Constructing an immunos… (10.1016/j.cpt.2024.07.004)
Abstract ORCID
67.12 21
4 Co-culture models for investigating cellular crosstalk in th… (10.1016/j.cpt.2023.11.002)
Abstract ORCID
63.94 18
5 Despicable role of epithelial–mesenchymal transition in brea… (10.1016/j.cpt.2024.01.001)
Abstract ORCID
58.80 14
6 Overview of skin cancer types and prevalence rates across co… (10.1016/j.cpt.2024.08.002)
Abstract
56.14 175
7 Role of T cells in cancer immunotherapy: Opportunities and c… (10.1016/j.cpt.2022.12.002)
Abstract
51.80 117
8 PI3K/AKT/mTOR pathway, hypoxia, and glucose metabolism: Pote… (10.1016/j.cpt.2022.09.001)
Abstract
46.58 72
9 Advances in nanoparticle-mediated cancer therapeutics: Curre… (10.1016/j.cpt.2024.11.002)
Abstract
46.13 69
10 Inflammatory cytokines and specific factors influencing lung… (10.1016/j.cpt.2025.04.002)
Abstract ORCID
45.15 7
11 Effects of aspirin on colon cancer using quantitative proteo… (10.1016/j.cpt.2023.06.003)
Abstract ORCID
42.25 6
12 Cardiotoxicity in platinum-based chemotherapy: Mechanisms, m… (10.1016/j.cpt.2024.04.004)
Abstract
40.84 42
13 Characteristics and outcomes of secondary acute lymphoblasti… (10.1016/j.cpt.2024.06.007)
Abstract ORCID
38.91 5
14 Biomaterial-based in vitro 3D modeling of glioblastoma multi… (10.1016/j.cpt.2023.01.002)
Abstract
36.18 27
15 Phytoconstituents as emerging therapeutics for breast cancer… (10.1016/j.cpt.2025.02.006)
Abstract
36.18 27
16 Autophagy as a targeted therapeutic approach for skin cancer… (10.1016/j.cpt.2024.01.002)
Abstract
35.78 26
17 Distinct T helper cell-mediated antitumor immunity: T helper… (10.1016/j.cpt.2022.11.001)
Abstract
35.37 25
18 Intraoperative glioblastoma surgery-current challenges and c… (10.1016/j.cpt.2023.11.006)
Abstract
35.37 25
19 Efficacy and safety of first-line treatment for metastatic t… (10.1016/j.cpt.2023.06.002)
Abstract
34.95 24
20 Overall survival associated with surgery, radiotherapy, and… (10.1016/j.cpt.2023.08.003)
Abstract ORCID
34.95 4
21 Epithelial–mesenchymal transition (EMT) and its role in acqu… (10.1016/j.cpt.2024.07.001)
Abstract
34.95 24
22 Volatile organic compounds in exhaled breath: Applications i… (10.1016/j.cpt.2024.12.004)
Abstract
34.51 23
23 Dynamics of epithelial–mesenchymal plasticity driving cancer… (10.1016/j.cpt.2024.07.002)
Abstract
34.04 22
24 Association between high body mass index and prognosis of pa… (10.1016/j.cpt.2023.03.002)
Abstract
33.56 21
25 Claudin-9 (CLDN9) promotes gastric cancer progression by enh… (10.1016/j.cpt.2024.09.006)
Abstract
32.53 19
26 Circular RNA vaccines: Pioneering the next-gen cancer immuno… (10.1016/j.cpt.2024.11.003)
Abstract
32.53 19
27 Chemoresistance: The hidden barrier in cancer treatment (10.1016/j.cpt.2025.07.001)
Abstract
31.97 18
28 Investigating hypoxia-inducible factor signaling in cancer:… (10.1016/j.cpt.2025.07.003)
Abstract
31.97 18
29 Exploring the significance of extracellular vesicles: Key pl… (10.1016/j.cpt.2024.04.005)
Abstract
30.76 16
30 Spices and culinary herbs for the prevention and treatment o… (10.1016/j.cpt.2024.07.003)
Abstract
30.76 16
31 Role of Candida albicans in chronic inflammation and the dev… (10.1016/j.cpt.2025.03.002)
Abstract
30.76 16
32 Oncofertility: Treatment options from bench to bedside (10.1016/j.cpt.2023.05.001)
Abstract
30.10 15
33 Preimplantation genetic testing for embryos predisposed to h… (10.1016/j.cpt.2023.05.002)
Abstract
30.10 15
34 Risk of interstitial lung disease with the use of programmed… (10.1016/j.cpt.2023.08.002)
Abstract ORCID
30.10 3
35 Experimental models for cancer brain metastasis (10.1016/j.cpt.2023.10.005)
Abstract
28.65 13
36 Landscape of the clinical development of China innovative an… (10.1016/j.cpt.2022.10.003)
Abstract
27.85 12
37 RNA splicing alterations in lung cancer pathogenesis and the… (10.1016/j.cpt.2023.04.004)
Abstract
27.85 12
38 Emerging role of transforming growth factor-β-regulated long… (10.1016/j.cpt.2022.12.003)
Abstract
26.98 11
39 Pathological significance of heme oxygenase-1 as a potential… (10.1016/j.cpt.2023.04.001)
Abstract
26.03 10
40 Common endocrine system adverse events associated with immun… (10.1016/j.cpt.2023.11.005)
Abstract
26.03 10
41 Mushrooms as potent autophagy modulators in cancer therapy:… (10.1016/j.cpt.2025.08.001)
Abstract
26.03 10
42 Dachaihu decoction inhibits hypernutrition-induced liver met… (10.1016/j.cpt.2023.02.003)
Abstract
25.00 9
43 Reversal of the immunosuppressive tumor microenvironment via… (10.1016/j.cpt.2023.07.003)
Abstract
25.00 9
44 Diagnosis of choroid plexus papilloma: Current perspectives… (10.1016/j.cpt.2023.09.005)
Abstract
25.00 9
45 An overview of randomized phase III clinical trials of cance… (10.1016/j.cpt.2024.10.001)
Abstract
25.00 9
46 Arthropod venom peptides: Nanotechnology-enabled delivery an… (10.1016/j.cpt.2025.03.005)
Abstract
25.00 9
47 Emerging risk factors and the role of gut microbiota in immu… (10.1016/j.cpt.2025.06.007)
Abstract
25.00 9
48 Exploring marine-derived compounds as potential anticancer a… (10.1016/j.cpt.2025.08.004)
Abstract
25.00 9
49 Unusual presentation of gastric cancer during treatment of h… (10.1016/j.cpt.2023.01.003)
Abstract ORCID
23.86 2
50 Chimeric RNAs and their implication in prostate cancer (10.1016/j.cpt.2023.04.003)
Abstract
23.86 8